Phase III
Loos, France-based Genfit announced it is planning an initial public offering (IPO) to raise $100 million. Genfit is a late-stage biopharma company focused on developing therapeutics for metabolic and liver diseases. The area that has the most interest is nonalcoholic steatohepatitis, or NASH.
The drug is being developed and commercialized jointly by AstraZeneca and Merck. It has already been approved for multiple indications in advanced ovarian cancer and metastatic breast cancer.
Roche’s Flatiron Health and the U.S. Food and Drug Administration’s Information Exchange and Data Transformation (INFORMED) Program expanded a two-year-old collaboration agreement.
For its 2019 list of the top 50 most innovative companies, Fast Company selected 10 from the biotech industry that are having a significant impact on the treatment of patients. The first five are highlighted.
Keytruda failed to show a statistical significance in overall survival and progression free survival in the Phase III trial.
When your back hurts, your whole body hurts. This morning, Pfizer and Eli Lilly reported positive results from its Phase III back pain treatment tanezumab.
Intercept Pharma plans to seek regulatory approval in the U.S. and Europe in the second half of this year.
Merck’s Keytruda paired with Pfizer’s Inlyta fares better than standard-of-care treatment in patients of advanced renal cell carcinoma.
As the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) rolls on, companies are showcasing more data in presentations. BioSpace takes a look at some of the latest.
Denmark’s H. Lundbeck and Japan’s Otsuka Pharmaceutical announced that their brexpiprazole failed to meet its primary endpoint in two Phase III clinical trials to treat manic episodes in patients with bipolar I disorder.
PRESS RELEASES